TICKERNERD
Menu
ALECALECHealthcare · Biotechnology

ALEC Stock Forecast: Alector, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.02
+5.21% on the day

The 7 Wall Street analysts covering Alector, Inc. hold a median 12-month price target of $3 — +48.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$202.1M
Ticker Nerd rank
50 / 100
Median analyst target
$3.00
Analysts covering
7
Revenue$3.3M−57.8% y/y
Operating income−$24.4M
Net income−$23.0M
Free cash flow−$34.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.6%
1M
−18.2%
YTD
+29.5%
1Y
−34.4%
From 52W high
−39.0%
From 52W low
+77.2%
$1.14
$3.31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALEC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alector, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
76
Size
66
Issuance
65
Momentum
56
Accruals
44
Value
40
Growth
37
Quality
31
Volatility
28

Revisions (76): Analysts have, on balance, been raising their forecasts.

Volatility (28): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALEC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALEC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26ALECHigh $6.00Median $3.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
3 Buy2 Hold2 Sell
Low $1.00Median $3.00High $6.00

The green dot is the last close — the median target sits +48.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Apr 2026Cantor FitzgeraldUpgradeOverweight—
10 Mar 2026BTIGUpgradeBuy—
22 Oct 2025BTIGDowngradeNeutral—
22 Oct 2025Cantor FitzgeraldDowngradeNeutral—
22 Oct 2025HC Wainwright & Co.MaintainsBuy—
22 Oct 2025TD CowenDowngradeHold—
22 Oct 2025William BlairDowngradeMarket Perform—
25 Sept 2025BTIGReiteratesBuy—
28 July 2025MizuhoUpgradeOutperform—
9 May 2025HC Wainwright & Co.MaintainsBuy—
7 Mar 2025Morgan StanleyAssumesUnderweight$3.00 → $1.50
27 Feb 2025HC Wainwright & Co.ReiteratesBuy—
16 Dec 2024StifelDowngradeHold—
26 Nov 2024BTIGMaintainsBuy—
26 Nov 2024Cantor FitzgeraldReiteratesOverweight—
26 Nov 2024Morgan StanleyDowngradeUnderweight—
7 Nov 2024HC Wainwright & Co.ReiteratesBuy—
17 Sept 2024Cantor FitzgeraldReiteratesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
29 July 2024Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALEC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALEC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Alector, Inc. returned −34.4% against +16.2% for the S&P 500, dividends included.

ALEC vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ALECS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALEC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
3
Fundamentals

Alector, Inc. (ALEC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 84% of US stocks

Price / sales
14.6×

Cheaper than 11% of US stocks

Price / book
−20.1×

Cheaper than 98% of US stocks

EV / EBITDA
−0.5×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
−57.8%

Higher than 5% of US stocks

Earnings growth (YoY)
−57.8%

Higher than 9% of US stocks

Gross margin
—
Operating margin
−734.7%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−385.1%

Higher than 4% of US stocks

Return on assets
−27.6%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alector, Inc. (ALEC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alector, Inc. has a market value of $202.1M and an enterprise value of $62.1M.

  • Revenue in the twelve months to 30 June 2026: $13.9M. The latest quarter shrank 57.8% year on year.

  • Net income over the same four quarters: −$117.9M, a −850.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.10.

  • Free cash flow in the twelve months to 30 June 2026: −$158.4M.

  • Shares outstanding: 111.7M.

  • Trailing P/E: −1.3×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Alector, Inc. employs 103 people — $135K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ALEC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALECAlector, Inc.$202.1M
50
GLSIGreenwich LifeSciences, Inc.$222.2M
42
SIONSionna Therapeutics, Inc.$218.7M
30
PLXProtalix Biotherapeutics, Inc.$217.5M
92
PRQRProQR Therapeutics NV$216.8M
48
IFRXInflaRx NV$225.4M
7
MGNXMacroGenics, Inc.$225.6M
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alector, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALEC news & analysis

Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline

GlobeNewsWire · 7 Oct 2026neutral

Alector will host a virtual research and development event highlighting its wholly owned Alector Brain Carrier-enabled pipeline. The agenda will feature progress on AL137, AL164, and AL062.

Why it matters — The event will provide ALEC watchers with updates on three programs spanning anti-amyloid beta, tau siRNA, and alpha-synuclein siRNA approaches.

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Reuters · 5 Oct 2026positive

Roche has agreed to pay up to $1.27 billion to license Alector's experimental Parkinson's disease treatment, the US biotech announced on Monday. The news sent Alector's shares surging 72% in premarket trading.

Why it matters — This licensing deal with Roche provides Alector with significant potential financial upside and validation for its Parkinson's therapy program, marking a major corporate development for the company.

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases

GlobeNewsWire · 5 Oct 2026positive

Alector has entered a global license agreement with Genentech, granting Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy for Parkinson's disease and other neurodegenerative conditions. AL050 is enabled by Alector's Brain Carrier (ABC), its proprietary blood-brain barrier delivery platform.

Why it matters — This agreement validates Alector's proprietary ABC blood-brain barrier delivery platform and could represent a significant commercial opportunity for its pipeline in neurodegeneration.

FAQ

Frequently asked questions about ALEC stock

What is the ALEC stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Alector, Inc. have a median 12-month price target of $3, with estimates ranging from $1 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALEC stock a buy right now?

Of the 7 analysts covering Alector, Inc., 3 rate it a Buy, 2 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Alector, Inc. 50 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALEC?

As at 8 Oct 2026, Alector, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (76 of 100).

Will ALEC stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +48.5% from the last close, and Ticker Nerd's factor model ranks Alector, Inc. 50 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALEC stock forecast for 2030?

No analyst covering Alector, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALEC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $6 over the next 12 months.

How has ALEC stock performed over the past year?

Alector, Inc. returned -34.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alector, Inc. do?

Alector Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases.

What is the latest news on ALEC?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline". Alector will host a virtual research and development event highlighting its wholly owned Alector Brain Carrier-enabled pipeline. The agenda will feature progress on AL137, AL164, and AL062.

Company

About Alector, Inc.

Alector Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. Alector Inc. applies its immuno-neurology platform to target the immune dysfunction and protein-related pathology associated with conditions such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia. The company’s current portfolio includes monoclonal antibody and other biologic programs designed to restore healthy immune function in the brain, supported by biomarker-guided clinical development. It also advances Alector Brain Carrier, a proprietary blood-brain barrier platform intended to improve therapeutic delivery to the central nervous system. Headquartered in South San Francisco, California, Alector Inc. operates as a research-driven biopharmaceutical company with a focus on translating genetics, immunology, and neuroscience into treatments for severe brain disorders.

CEO Dr. Arnon Rosenthal Ph.D. · 103 employees · United States · https://www.alector.com